HCM today
$14.92+$0.07 (+0.47%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourBearish
1 hourBearish
15 minDescending Triangle
5 minConsolidating
Daily trend turns up above $15.70
Key levels
Resistance$15.48
Resistance$14.94
Support$14.32
Support$13.67
Latest news & SEC filings
ProductHUTCHMED's sovleplenib wins FDA rare-disease status for AIHA
ProductHUTCHMED submits paperwork in Europe and Japan for ORPATHYS plus TAGRISSO
All HCM news →About HUTCHMED
HUTCHMED is a biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. Its main products include Elunate, Fruzaqla, Sulanda, Orpathys and Tazverik, developed through its Oncology/Immunology operations in China and internationally. The company also operates a pharmaceutical distribution business in China and holds an equity interest in Shanghai Hutchison Pharmaceuticals. It operates primarily in China, with additional activities in the United States, Hong Kong and Europe.
Based on the company's 20-F filed Mar 5, 2026.
Nasdaq · Healthcare
HUTCHMED (China) Ltd (HCM)
What Is the Price Target for HCM?
SEPT Low Target
$14.00
SEPT Mid Target
$14.00
SEPT High Target
$14.00
Analyst Consensus
$14.00
Is HCM a Buy or Sell Right Now?
Thesis
- •Revenue growing -13.0% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for HCM.
Start Free Trial →Is HCM Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, Analyst Consensus
Fair Value
$12.16
55
Moat Score
NARROW
4/9
Piotroski Score
14.4
Altman Z-Score
What Is Smart Money Doing with HCM?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →HCM Growth Story
Revenue YoY
-13.0%
3yr Revenue CAGR
8.8%
EPS Growth YoY
1200%
FCF Growth YoY
-352.0%
Revenue Trend
STRONG
Dark Pool Trades for HCM
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for HCM, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:57:52 | $14.82 | 1,451 | $$22K | SELL |
| 14:31:00 | $15.05 | 1,433 | $$22K | MIDPOINT |
| 09:11:40 | $15.30 | 1,033 | $$16K | SELL |
| 16:01:30 | $15.39 | 4,812 | $$74K | BUY |
| 16:01:30 | $15.40 | 1,721 | $$27K | BUY |
5 dark pool trades shown · $$159K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for HUTCHMED (China) Ltd (HCM) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →HCM — frequently asked questions
What is HCM stock price today?
HUTCHMED (China) Ltd (HCM) is at $14.92, up 0.47% (+$0.07) at the Nov 13, 2026 close.
Why is HCM stock moving today?
Latest HCM news — Nov 5, 2026: HUTCHMED's sovleplenib wins FDA rare-disease status for AIHA · Nov 2, 2026: HUTCHMED submits paperwork in Europe and Japan for ORPATHYS plus TAGRISSO
What is the HCM price target?
The average analyst price target for HCM is $14.00, ranging from $14 to $14, based on 1 analysts. Latest: Goldman Sachs maintains on Jul 23, 2026.
What do analysts rate HCM?
Analyst ratings for HCM: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did HCM beat earnings?
HCM last reported on Jul 30, 2026: EPS $0.05 vs $0.14 expected — a miss of 68.3%.
Does HCM pay a dividend?
HCM does not currently pay a dividend.
How much debt does HCM have?
HUTCHMED (China) Ltd reported $93M of debt and $71M of cash (Dec 31, 2025).
What are HCM support and resistance levels?
Support: $14.32, $13.67, $13.02. Resistance: $14.94, $15.48, $16.33.
What are insiders doing with HCM?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on HCM?
Nov 5, 2026: HUTCHMED's sovleplenib wins FDA rare-disease status for AIHA · Nov 2, 2026: HUTCHMED submits paperwork in Europe and Japan for ORPATHYS plus TAGRISSO